| 摘要: |
| 新兴技术的发展,推动数字疗法逐渐流行,软件已成为医疗产品的重要组成部分。具有诊断、预防、治疗等功能的软件(Software as a Medical Device,SaMD)作为医疗器械软件的子集,亦属于数字医疗范畴,但由于国内外尚无对其完整全面的评估与监管体系,其监管问题亟需加强监管研究。本文通过介绍SaMD相关概念及政策、人工智能背景下SaMD面临的监管挑战、我国和WHO对数字医疗的管理原则等情况,使读者获悉为加强SaMD审评与监管的思路,以期对完善我国SaMD监管原则提供启示。 |
| 关键词: 数字健康 监管框架 监管原则 医疗器械 独立软件 |
| DOI:10.13506/j.cnki.jpr.2024.04.009 |
| 基金项目: |
|
Publication Date:April 25, 2024
|
|
| Preliminary study on the application of digital medical supervision principle in software as a medical device in China |
| WANG Ying |
| (Shanghai Center for Adverse Drug and Medical Device Reaction Monitoring, Shanghai 200040, China) |
| Abstract: |
| The development of emerging technologies has promoted the popularity of digital therapy, and software has become an important part of medical products. Software as a Medical Device (SaMD) with the functions of diagnosis, prevention and treatment, as a subset of medical device software, also belongs to the category of digital medical care. However, due to the lack of a complete and comprehensive evaluation and supervision system at home and abroad, it is urgent to strengthen supervision research on its supervision. This paper introduces the related concepts and policies of SaMD, the regulatory challenges faced by SaMD under the background of artificial intelligence, and the management principles of digital medical care in China and WHO, so as to inform readers of the ideas for strengthening the review and supervision of SaMD, with a view to providing enlightenment for improving the regulatory principles of SaMD in China. |
| Key words: Digital health Regulatory framework Regulatory principles Software as a Medical Device |